Skip to main content

Table 1 Associations between ZNF331 methylation and clinical and molecular features

From: Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer

 

Total

ZNF331 unmethylated

ZNF331 methylated

P value

n

n (%)

n (%)

No. of patients

423

122 (29)

301 (71)

 

Gender

   

0.165

 Male

213

68 (32)

145 (68)

 

 Female

210

54 (26)

156 (74)

 

Age

   

0.074

 < 60

70

26 (37)

44 (63)

 

 60–74

178

55 (31)

123 (69)

 

 ≥ 75

175

41 (23)

134 (77)

 

Stage

   

0.683

 I

79

20 (25)

59 (75)

 

 II

169

51 (30)

118 (70)

 

 III

118

32 (27)

86 (73)

 

 IV

56

19 (34)

37 (66)

 

Localization

   

< 0.001

 Right colon

167

27 (16)

140 (84)

 

 Left colon

130

47 (36)

83 (64)

 

 Rectum

121

46 (38)

75 (62)

 

MSI status

   

< 0.001

 MSS

325

111 (34)

214 (66)

 

 MSI

89

8 (9)

81 (91)

 

BRAF

   

< 0.001

BRAF wt

356

120 (34)

236 (66)

 

BRAF mut

67

2 (3)

65 (97)

 

CIMP

   

< 0.001

CIMP−

355

121 (34%)

234 (66)

 

CIMP+

65

0 (0)

65 (100)

 

MLH1 methylation

   

< 0.001

MLH1 unmeth

360

117 (32.5)

243 (67.5)

 

MLH1 meth

60

4 (7)

56 (93)

 

Series

   

0.439

 Oslo 3

59

14 (24)

45 (76)

 

 Oslo 2

364

108 (30)

256 (70)

 
  1. Meth methylated, mut mutation, No. number, unmeth unmethylated, wt wild type